A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Geoffrey L. Uy, Michael P. Rettig, Ibraheem H. Motabi, Kyle McFarland, Kathryn M. Trinkaus, Lindsay M. Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith E. Stockerl-Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio

Research output: Contribution to journalArticle

247 Scopus citations

Abstract

The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse. We hypothesized that inhibition of the CXCR4/CXCL12 axis by the small molecule inhibitor, plerixafor, would disrupt the interaction of leukemic blasts with the environment and increase the sensitivity of AML blasts to chemotherapy. In this phase 1/2 study, 52 patients with relapsed or refractory AML were treated with plerixafor in combination with mitoxantrone, etoposide, and cytarabine. In phase 1, plerixafor was escalated to a maximum of 0.24 mg/kg/d without any dose-limiting toxicities. In phase 2, 46 patients were treated with plerixafor 0.24 mg/kg/d in combination with chemotherapy with an overall complete remission and complete remission with incomplete blood count recovery rate (CR + CRi) of 46%. Correlative studies demonstrated a 2-fold mobilization in leukemic blasts into the peripheral circulation. No evidence of symptomatic hyperleukocytosis or delayed count recovery was observed with the addition of plerixafor. We conclude that the addition of plerixafor to cytotoxic chemotherapy is feasible in AML, and results in encouraging rates of remission with correlative studies demonstrating in vivo evidence of disruption of the CXCR4/CXCL12 axis. This study was registered at www.clinical trials.gov, no. NCT00512252.

Original languageEnglish
Pages (from-to)3917-3924
Number of pages8
JournalBlood
Volume119
Issue number17
DOIs
StatePublished - Apr 19 2012

Fingerprint Dive into the research topics of 'A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this